Synthetic Drugs BLOG

A little more than two months after its temporary placement into drug scheduling, the controversial drug U-47700 is now confirmed by the Drug Enforcement Agency (DEA) to fall under Schedule I of the Controlled Substances Act.

This move by DEA came after several reports of the adverse effects of U-47700 use, which led to 46 confirmed deaths, most of which were recorded in New York. The placement of the drug under its current schedule will take effect starting today, November 14, 2016, and will last for 24 months.

During this period, DEA will ascertain the correct schedule placement of U-47700, and is granted an extra 12 months to maintain the drug's schedule until enough data has been collected and assessed.

It is under the DEA's jurisdiction and power to implement emergency scheduling of drugs, especially those that may affect a significant portion of the society. In the case of U-47700, the sheer number of fatalities and health risks involved in the use of the substance warranted the agency to perform such action.

The questionable drug has euphoric effects that far exceed those of heroin, but some black market dealers label U-47700 as heroin to deceive unsuspecting users. What's more dangerous about U-47700 is that it can be marketed as colorful pills, hence its street name Pinky.

During the assessment period, DEA should look into the drug's chemical composition, its pattern and scope of abuse, and level of risk to public health.